## Key Dates

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 April</td>
<td>ACT-A Announced&lt;br&gt;co-Hosts: WHO, EC, France, BMGF&lt;br&gt;supporting: UN SG, Heads of State/Govt, agencies</td>
</tr>
<tr>
<td>4 May</td>
<td>EURO 9.8 B pledge event (incl. COVID response)</td>
</tr>
<tr>
<td>20 May</td>
<td>World Health Assembly Resolution</td>
</tr>
<tr>
<td>4 June</td>
<td>ACT-A Consolidated Roadmap</td>
</tr>
<tr>
<td>27 June</td>
<td>US$ 6.9 B pledge event (incl. COVID response)</td>
</tr>
</tbody>
</table>
The ACT goal: reduce COVID19 mortality & severe disease through accelerated development, equitable allocation & scaled up delivery of...

- **Vaccines**: 2 billion doses by the end of 2021
- **Therapeutics**: 245 million courses by mid-2021
- **Diagnostics**: 500 million tests by mid-2021

...thereby protecting health systems & restoring societies & economies
The ACT-Accelerator - Pillars drive the work

• 3 vertical Pillars are the primary drivers of ACT’s product work
• A cross-cutting Access & Allocation Workstream drives for equity
• A Health Systems Connector drives optimal utilization
• Support mechanisms incl. 2 Special Envoys, ACT VCs, ACT Support Hub
ACT leverages the best of international health in coordination with WHO

**Coordination & Support**

- World Health Organization

**Cross-cutting**

**Access & Allocation**

- World Health Organization

**All Pillars**

- Norms & Standards
- Regulatory/PQ
- Policy & Technical guidance

---

**Vaccines**

- CEPI
- Gavi

- Development & manufacturing
- Policy & allocation
- Procurement & delivery at scale

**Therapeutics**

- Wellcome
- Unitaid

- Rapid assessment of candidates
- Market preparedness
- Deployment in all countries
- Costing & financing

**Diagnostics**

- FIND
- TheGlobalFund

- R&D
- Market readiness tools
- Supply
- Country preparedness

---

**Health Systems Connector**

- TheGlobalFund
- The World Bank

- Integrated data mgmt
- Financing
- Community-led responses
- Private sector
- Key supply elements supply chain

---

**In discussion**

- Country systems
- Protect frontline workers
- Clinical care
WHO’s most senior staff lead its engagement in ACT

**Vaccines**
- **Chief Scientist**
  - Dr Soumya Swaminathan
- **CEPI**
- **Gavi**

**Therapeutics**
- **Assistant Director-General**
  - Dr Mariângela Simão
- **Unitaid**
- **Wellcome**

**Diagnostics**
- **Assistant Director-General**
  - Dr Hanan Balkhy
- **The Global Fund**
- **FIND**

**Access & Allocation**
- **Assistant Director-General**
  - Dr Mariângela Simão

**Health Systems Connector**
- **Deputy Director-General**
  - Dr Zsuzsanna Jakab
A high-level timeline communicates ACT’s work

<table>
<thead>
<tr>
<th>Phase 1: Substantive expansion of access to existing diagnostics &amp; identification of viable new tools for large-scale use</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
</tr>
<tr>
<td>Q2</td>
</tr>
<tr>
<td>Phase 2: Introduction of multiple new tools to complement NPIs</td>
</tr>
<tr>
<td>2021</td>
</tr>
<tr>
<td>Q1</td>
</tr>
<tr>
<td>Phase 3: Transition to new tools as primary intervention to COVID-19</td>
</tr>
</tbody>
</table>

- Production initiated based on robust, expedited assessment of a broad range of new products & platforms
- Rollout in priority populations, using the allocation mechanism in support of the public health goal
- Availability of new tools at sufficient scale to advance control of the pandemic

This high-level timeline anchors the comprehensive plans developed by the Pillars. Work across the 4 Pillars would be adapted to the evolving epidemiology, trial results, and tools.
Core assumptions guide ACT’s priorities

Overarching assumptions

• The substantial gaps in immunity to COVID-19 globally will result in continued & substantial waves of disease through at least end-2021, straining health systems and further disrupting societies and economies.

• There are multiple potential approaches to change spread & profile of COVID-19, thereby restoring functional societies & economies; further innovation is key to finding new solutions as NPI’s alone will not be sufficient.

Vaccines

• An innovative-platform based vaccine could be available by end-2020 but with limited supply; quantities for key subgroups could be available in Q1-2 2021 with broader use and additional products from Q3 2021.

Therapeutics

• New molecules or biologics, will be needed to achieve significant reductions in mortality and/or morbidity (repurposing existing drugs is unlikely to be sufficient); these products may have higher costs, supply limitations and other access challenges.

Diagnostics

• Expansion of PCR technologies is the near term solution for the global diagnostics challenge; innovation (e.g., rapid antigen diagnostic) would substantially facilitate the global response.

Health systems strengthening

• Local capacities must be substantially strengthened to optimize in country delivery of new COVID-19 tools, including for ‘the last mile’.
Key documents underpin the work of ACT

Consolidated ACT Investment Case
Incl. Pillar targets & urgent financing needs over next 6 & 12 months

Consolidated ACT Roadmap
Incl. goal, core assumptions, high-level timeline, deliverables

Released: 26 June 2020
Target date: mid-July 2020
Financing the consolidated investment case for the Vaccines, Therapeutics & Diagnostics Pillars (at 1 July 2020)

**ACT-Accelerator needs**
(over the next 12 months for Diagnostics and Therapeutics and 18 months for Vaccines)

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immediate need:</strong> US$17.1 Billion</td>
<td><strong>Total need:</strong> US$31.3 Billion</td>
</tr>
</tbody>
</table>

**Proportion funded | Immediate needs | Total needs | % of total need pledged**

**Vaccines**
- Proportion funded: $2.7Bn
- Immediate needs: $11.3Bn
- Total needs: $18.1Bn for next 18 months
- % of total need pledged: 15%

**Therapeutics**
- Proportion funded: $0.7Bn
- Immediate needs: $3.8Bn
- Total needs: $7.2Bn for next 12 months
- % of total need pledged: 10%

**Diagnostics**
- Proportion funded: $0.4Bn
- Immediate needs: $2.0Bn
- Total needs: $6.0Bn for next 12 months
- % of total need pledged: 5%
The ACT Partnership – already delivering selected achievements since 24 April

• **9 vaccine** candidates already in COVAX portfolio; 6 in trials

• **Global COVAX Vaccines Facility** launched, 300 m doses already secured & Advance Market Commitment (AMC) issued

• **1 new therapeutic** demonstrated effectiveness

• **50+ test kits** under evaluations & **10+ million kits** procured

• **Ethical Access Principles** agreed and **Allocation Framework** under consultation with Member States
The ACT Accelerator Call to Action

Our Commitment

1. We commit to the shared aim of equitable global access to innovative tools for COVID-19 for all.

2. We commit to an unprecedented level of partnership — proactively engaging stakeholders, aligning and coordinating efforts, building on existing collaborations, collectively devising solutions, and grounding our partnership in transparency, and science.

3. We commit to create a strong unified voice to maximize impact, recognizing this is not about singular decision-making authority, but rather collective problem-solving, interconnectedness and inclusivity, where all stakeholders can connect and benefit from the expertise, knowledge and activities of this shared action-oriented platform.

4. We commit to build on past experiences towards achieving this objective, including ensuring that every activity we undertake is executed through the lens of equitable global access, and that the voices of the communities most affected are heard.

5. We commit to be accountable to the world, to communities, and to one another. We are coming together in the spirit of solidarity, and in the service of humanity, to achieve our mission and vision.

“We ask the global community and political leaders to support this landmark collaboration, and for donors to provide the necessary resources to accelerate achievement of the objectives of this global collaboration.”

Further information:

ACTaccelerator@who.int